Hinge Health, Inc.
NYSE:HNGEMedical - Healthcare Information Services
-$0.24 today
- Market cap
- $9.31B
- Beta
- 1.99
- P/E (TTM)
- -10.3
- EPS (TTM)
- -$6.49
Volume 1.23M
Average 1.34M
HNGE Revenue
Total income from selling goods and services before any costs are deducted; the top line of the income statement.
Hinge Health, Inc.NYSE: HNGE
Revenue · Q2 FY2026 · quarter ended Jun 2026
Revenue growth accelerates
Q2 FY2026 revenue of $212.82M rose 53.0% year over year, ahead of the +49.8% change in trailing-twelve-month revenue. Sequentially, it rose 16.7% from the prior quarter.
Context
- Revenue increased in 2 of the last 2 fiscal years.
- FY2025 was the highest annual figure in the 3 fiscal years shown.
What to watch
Whether revenue reaches the consensus estimate from 12 analysts of $879.41M (+49.6%) for the fiscal year ending Dec 2026, a pace similar to FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- $212.82M+16.7% QoQ
- Last fiscal yearDec 2025
- $587.86M+50.6% YoY
- LTMJun 2026
- $720.06M+49.8% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +53.0% | +45.8% | -7.2 pp |
| 1 year | +50.6% | +49.6% | -1.0 pp |
| 3-year CAGR | — | +32.8% | — |
| 5-year CAGR | +29.0% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Revenue history
USD · from the income statement
- Latest · FY2025
- 587.86M USD
- Year-over-year change
- +50.6%
- 2-year CAGR
- +41.7%
| Period | Period end | Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 587.86M | +50.6% |
| FY2024 | 2024-12-31 | 390.4M | +33.4% |
| FY2023 | 2023-12-31 | 292.73M | — |
Revenue vs competitors
How HNGE compares with its peers on the latest reported figures
- HNGE's LTM Jun 2026 revenue of $720.06M is the 4th highest of the 5 companies compared; the peer median is $1.5B.
- Its year-over-year change of +49.8% is the highest of 5, against a peer median of +7.6%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| FY2025 | $6.16B | +6.1% | +5.7% | |
| LTM Apr 2026 | $2.28B | +6.0% | +12.9% | |
| LTM Mar 2026 | $729.22M | +9.1% | +12.2% | |
| LTM Jun 2026 | $720.06M | +49.8% | — | |
| LTM Mar 2026 | $283.3M | +49.4% | +42.9% | |
| Peer median (excluding HNGE) | $1.5B | +7.6% | +12.5% | |
Competitors are the stored peer set for HNGE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|
| Revenue | 292.73M | 390.4M | 587.86M |
| Cost of Revenue | 98.55M | 89.81M | 118.56M |
| Gross Profit | 194.18M | 300.59M | 469.3M |
| Gross Margin | 66.3% | 77.0% | 79.8% |
| Research & Development | 110.06M | 100.84M | 368.14M |
| Selling, General & Admin | 214.64M | 227.54M | 639.41M |
| Operating Expenses | 324.69M | 332.5M | 1.02B |
| Depreciation & Amortization | 5.63M | 5.95M | 5.13M |
| EBITDA | (124.89M) | (18.48M) | (535.89M) |
| EBITDA Margin | -42.7% | -4.7% | -91.2% |
| Operating Income | (130.51M) | (31.91M) | (546.37M) |
| Operating Margin | -44.6% | -8.2% | -92.9% |
| Interest Income | 0 | 0 | 0 |
| Interest Expense | 0 | 0 | 0 |
| Other Income / Expenses | 21.97M | 20.65M | 19.11M |
| Income Before Tax | (108.55M) | (11.26M) | (527.26M) |
| Pre-Tax Margin | -37.1% | -2.9% | -89.7% |
| Income Tax Expense | (405K) | 677K | 998K |
| Net Income | (108.14M) | (11.93M) | (528.26M) |
| Net Margin | -36.9% | -3.1% | -89.9% |
| EPS (Basic) | (1.39) | (0.15) | (5.36) |
| EPS (Diluted) | (1.39) | (0.15) | (5.19) |
| Weighted Avg Shares | 78.02M | 78.02M | 79.19M |
| Weighted Avg Shares (Diluted) | 78.02M | 78.02M | 81.7M |
Hinge Health, Inc.
NYSE:HNGE
Intrinsic Alpha fair value
Locked
Current Price
$114.53
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.